Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

US biotech OPKO Health (Nasdaq: OPK) and Israeli firm Entera Bio (Nasdaq: ENTX) have entered into a collaboration to develop an oral GLP-1/glucagon dual agonist tablet for obesity, metabolic ...

Mumbai-based Kilitch Drugs Ltd plans to enter biosimilars and oral solids, including diabetic and weight-loss tablets, and is ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

My 66-year-old husband recently received a diagnosis of heart failure with preserved ejection fraction. He is 5 feet, 7 ...

When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off ...

GLP-1 medications are changing the way we approach weight loss and chronic conditions. Dr. Nima Mowzoon of UBI Telehealth ...

We recently published a list of Jim Cramer Was Talking About These 10 Stocks Amid Tariff Chaos. In this article, we are going to take a look at where The Campbell’s Company (NASDAQ:CPB) stands against ...

Honor is a mobiles, tablets, and wearables brand of Chinese telecommunications giant Huawei. Established in 2013, the largely-online brand contributes a significant proportion of Huawei's total sales ...